Vitrakvi
What Vitrakvi is used for
Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Vitrakvi
- Active substance
- larotrectinib
- Disease area
- Abdominal Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01XE53
- Marketing authorisation holder
- Bayer AG
- Authorised in the EU since
- 2019
Official information
In the USA
Same active substance: Vitrakvi
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vitrakvi used for?
Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options.
What is the active substance in Vitrakvi?
Vitrakvi contains larotrectinib.
Who makes Vitrakvi?
The EU marketing authorisation holder is Bayer AG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU